Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: May 15, 2025
Principal Executive Office: Marseille, France
Context: This filing serves as a vehicle to distribute a press release dated May 15, 2025 (Exhibit 99.1). The document itself contains no narrative business description or operational details beyond the cover page and signature block.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a procedural filing referencing an external press release and does not contain embedded financial statements or quantitative data.
Material Changes
No material changes versus the prior comparable period are described in the provided text. The document lacks comparative financial data or operational updates.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are presumably contained within the referenced Exhibit 99.1 (Press Release), the content of which is not included in the input.
Investor Verification Checklist
- Verify the content of the referenced Press Release (Exhibit 99.1) for the specific announcement triggering this filing.
- Confirm whether the press release contains updated clinical trial data, partnership agreements, or financial guidance.
- Review the company's most recent Form 20-F for the latest audited financial statements, as this 6-K does not include them.